Veeda Clinical Research Refiles IPO Documents With SEBI

Veeda Clinical Research Refiles ₹185 Crore IPO.

Expert Analysis:

• IPO Refiled: Veeda Clinical Research refiles its DRHP with SEBI for its IPO with a ₹2 face value shares,₹185 crore fresh issue, and 13 million shares for sale, initially submitted on September 27, 2021.

• Strong Financial Growth: Veeda's revenue grew at a 16.18% CAGR (FY22-FY24), with TAM projected to expand from USD 65.4B to USD 110.7B by 2028.

• Revenue & Client Growth: Veeda reported ₹305.30 crore revenue (H1 FY25) with 436 active clients, completing 580 studies in FY22, showcasing global market strength.

• Fund Allocation: Funds to be used for ₹50 crore for equipment, ₹35 crore for Bioneeds' capital expenditure, and ₹10.89 crore for Bioneeds' debt repayment to drive growth.

• Organic Growth Focus: ₹33 crore allocated for marketing, tech upgrades, and digital modernization to enhance efficiency and quality assurance.

• Regulatory Strength & IPO Management: 119 successful global inspections highlight Veeda’s compliance, with Axis Capital, CLSA, IIFL, and SBI Capital managing the IPO.

• Strategic Positioning: Veeda’s IPO aims to fund growth, strengthen its clinical research portfolio, and advance global healthcare R&D efforts.